UNIQURE NV's ticker is QURE and the CUSIP is N90064101. A total of 177 filers reported holding UNIQURE NV in Q4 2022. The put-call ratio across all filers is 0.23 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $68 | -41.9% | 10,200 | 0.0% | 0.00% | -100.0% |
| Q2 2023 | $117 | -42.9% | 10,200 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $205 | -11.3% | 10,200 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $231 | -99.9% | 10,200 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $191,000 | +0.5% | 10,200 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $190,000 | -10.8% | 10,200 | -13.6% | 0.00% | 0.0% |
| Q1 2022 | $213,000 | -13.1% | 11,800 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $245,000 | -35.2% | 11,800 | 0.0% | 0.00% | -50.0% |
| Q3 2021 | $378,000 | +61.5% | 11,800 | +55.3% | 0.00% | +100.0% |
| Q2 2021 | $234,000 | +10.4% | 7,600 | +20.6% | 0.00% | 0.0% |
| Q1 2021 | $212,000 | -7.0% | 6,300 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $228,000 | -1.7% | 6,300 | 0.0% | 0.00% | -50.0% |
| Q3 2020 | $232,000 | -18.3% | 6,300 | 0.0% | 0.00% | +100.0% |
| Q2 2020 | $284,000 | – | 6,300 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 841,471 | $15,786,000 | 5.69% |
| Nantahala Capital Management | 2,901,929 | $54,440,000 | 3.52% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 544,500 | $10,209,000 | 3.27% |
| 683 Capital Management, LLC | 1,373,600 | $25,768,000 | 1.99% |
| PFM Health Sciences, LP | 2,393,311 | $44,899,000 | 1.62% |
| Integral Health Asset Management, LLC | 433,000 | $8,123,000 | 1.58% |
| Privium Fund Management B.V. | 238,998 | $4,283,000 | 1.56% |
| Nantahala Capital Management | 1,000,000 | $18,760,000 | 1.21% |
| Henry James International Management Inc. | 89,469 | $1,678,000 | 0.94% |
| Altium Capital Management LP | 105,000 | $1,970,000 | 0.72% |